answer text |
<p>NHS England has routinely commissioned stereotactic ablative radiotherapy to treat
early non-small cell lung cancer since 2013, meaning that the evidence to support
its routine commissioning has already been established for patients that meet the
eligibility criteria described in the clinical commissioning policy. NHS England has
since reviewed the clinical evidence for later stage non-small cell lung cancer and
all stages of small cell lung cancer and a second policy is in development.</p><p>
</p><p><strong> </strong></p><p><strong> </strong></p>
|
|